InvestSource Inc.: Hall-of-Fame Jockey Jorge Velasquez

Tag : matching shoe
InvestSource Inc.: Hall-of-Fame Jockey Jorge Velasquez Appointed ToHybred International's Board of Advisers

Released : Monday, July 14, 2008 1:45 PM
RDATE:14072008
Stocks in the News: Hybred International, Inc., (PINKSHEETS: HYII),Eddie Bauer, Inc. (NASDAQ: EBHI), NeurogesX, Inc. (NASDAQ: NGSX),Bioheart, Inc. (NASDAQ: BHRT)
Jul 11, 2008 -- Hybred International, Inc., (PINKSHEETS: HYII)which has a patent-pending horseshoe that prevents injuries using abuilt-in shock absorber that protects horses hooves, announcedtoday that Hall of Fame jockey Jorge Velasquez has been appointedto the company's board of advisers. Velasquez is best known as theregular rider of racing's most famous runner-up, Alydar. In 1978 herode Alydar to three dramatic second-place finishes to Affirmed inthe Kentucky Derby, Preakness and Belmont. The Hall of Fame jockeyrode 6,795 races in his career, including winning the Breeders' CupClassic in 1985 atop Proud Truth as well as the 1981 Derby andPreakness aboard Pleasant Colony. Gary Kouletas, founder andpresident of Hybred International, said, "We are proud to haveJorge join our board of advisers and his confidence in the value ofthe Hybred Horseshoe. He understands how important this developmentis to horse racing." Velasquez said, "The Hybred Horseshoe with itsbuilt-in shock absorber for the horse, reduces the constantpounding that horses must endure on the track." Other members ofthe Hybred International Board of Advisors are Ian McKinlay, theleading authority on hoof lameness; Mike Wildenstein, professor atCornell University's renowned Farrier School, who recently wasinducted into the Farrier Hall of Fame.
Anaheim-based Thoro'Bred, Inc., the world's largest aluminumhorseshoe manufacturer, has agreed to make the shoes. It willmanufacture the aluminum part in California and ship the shoes to aplant in upstate New York, where urethane will be bonded onto it.
In addition, Thoro'Bred has agreed to market the shoe in itscatalogue and marketing materials and has granted HybredInternational the use of its customer and mailing lists, openingthe doors to virtually every domestic tack shop, farrier and supplystore in the U.S.
Jul 11, 2008 -- Eddie Bauer, Inc. (NASDAQ: EBHI) announced today anexclusive partnership with mountaineering legend Jim Whittaker,reestablishing a relationship initiated 45 years ago when Whittakerbecame the first American to summit Mt. Everest, the world'shighest peak. Eddie Bauer outfitted the historic 1963 Everestexpedition and subsequent climbs by Whittaker and otherworld-renowned mountaineers. In his new role with Eddie Bauer,Whittaker will consult on product development, assist withmarketing campaigns, and serve as a spokesperson for the brand. "Wecan't think of a more natural partnership than this one with Jim, atrue American pioneer whose heroic achievements have become aninspiration to us all," says Neil Fiske, President and CEO of EddieBauer. "His expertise, bold sense of adventure, and passion for theoutdoors will help us reinvigorate the brand, and return to ourroots as the original outdoor outfitter." Since 1953, Eddie Bauerhas been the foremost expedition outfitter, providing cold-weatherouterwear and gear for more than 40 major climbing expeditions allover the globe, including 5 first-world ascents, 4 first- Americanascents, and 3 first-route ascents.
"Eddie Bauer paved the way for expedition outfitting, and made hugestrides in outerwear technology," says Whittaker. "It's exciting tosee the company focus on what it's best at, and I look forward tosharing my experiences to help Eddie Bauer get back to the summit,literally and figuratively."
Jul 11, 2008 -- NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceuticalcompany focused on developing and commercializing novel painmanagement therapies, announced the initiation of its Phase 1clinical trial (study C203) of NGX-1998. The product candidate is ahigh-concentration, capsaicin-based liquid formulation designed todeliver a localized therapeutic dose directly to the pain site. Therandomized, single-blind Phase 1 trial is designed to evaluatepotential control formulations for future NGX-1998 clinical trials.NeurogesX expects to complete the trial by the end of 2008. AnthonyDiTonno, President and CEO of NeurogesX, commented, "The initiationof this Phase 1 trial of NGX-1998 marks a significant step in ourprogram to develop a second-generation liquid formulation ofcapsaicin to manage pain. We believe that our Phase 1 trial willprovide us with important information that will help shape thedesign of further studies with the product candidate. We arepleased with the Company's progress with NGX-1998 advancing in theclinic and NGX-4010 under regulatory review in Europe andapproaching NDA submission in the United States."
Jul 11, 2008 -- Bioheart, Inc. (NASDAQ: BHRT), a company committedto delivering intelligent devices and biologics that help monitor,diagnose and treat heart failure and cardiovascular diseases, todayannounced it has secured worldwide non-exclusive distributionrights to the Bioheart 3370 Heart Failure Monitor, an interactiveand simple-to-use at-home intelligent device designed specificallyto improve available healthcare to patients outside hospitals whoare suffering from heart failure. The device, manufactured by RTXHealthcare A/S (Denmark), has 510k market clearance from the USFood and Drug Administration for marketing in the U.S. and CE markapproval for marketing in Europe and other countries that followthis mark. The Company is planning to begin immediate commercialdistribution. The compact Bioheart 3370 Heart Failure Monitorengages patients through personalized daily interactions andquestions, while collecting vital signs and transmitting theinformation directly into a database. It is uniquely available inboth a wireless configuration and through hook-up to regulartelephone lines. The data are regularly monitored by a remotelylocated medical professional, who watches for any abnormal readingsthat may signal a change in the patient's health status. Thesechanges are reported back to the treating physician. "We are veryexcited about this tremendous opportunity to better serve theCongestive Heart Failure patient population and their physicians,"said Howard J. Leonhardt, Bioheart's CEO and Chief TechnologyOfficer. "This technology is highly synergistic to our work withMyoCell Therapy, an investigational cell therapy for the potentialtreatment of chronic heart damage, and marks the beginning of ourability to offer new intelligent devices that complement celltransplantation."
Market Wrap for July 11th, 2008
It was another volatile session on Wall Street as the Dow JonesIndustrial Average fell more than 200 points to break below 11,000for the first time in two years. It made its way back into positiveground, though only for a moment. Renewed pessimism sent the Dowmarkedly lower to finish the session with a 128 point loss. Stocksspent nearly the entire session trading with sizeable losses asinvestors continued to fret over Fannie Mae (FNM 10.25, -2.95) andFreddie Mac (FRE 7.75, -0.25). Only when a Reuters source indicatedthe two lenders would have access to the Fed's discount window didstocks rally into the green. The notion that capital would beavailable to the lenders if they were in dire need assuaged concernand lifted the shares; short-covering aided in the recovery.However, when the Fed would not confirm it would lend to Fannie orFreddie, stocks surrendered their gains. The concerns surroundingFannie and Freddie overwhelmed news from General Electric (GE27.66, +0.02), an enriched buyout bid for Anheuser-Busch (BUD66.50, +5.29), and encouraging economic data. For the secondquarter GE earned $0.54 per share matching the consensus earningsestimate. GE also announced it is divesting its consumer financebusiness in Japan for $5.4 billion. GE announced yesterday it isconsidering spinning off its consumer and industrial business. Thefirm is trying to focus on higher return opportunities. Belgianbrewer InBev increased its bid to acquire shares of BUD to $70 pershare, up from $65 per share, according to The Wall Street Journal.Shares of BUD climbed higher in response to the offer, unaffectedby the turmoil surrounding the broader market. Importantly, the Maytrade deficit narrowed to $59.8 billion from a revised $60.5billion in April. The real trade deficit fell to $43.6 billion from$46.7 billion in April. After trading off its highs in recentsessions, crude oil prices surged to a new record of $147.27 perbarrel in early trading, only adding to the session's pessimism. Itclosed its session just below the $145 per barrel mark.
ABOUT INVESTSOURCE, INC.: WIN an 8 day 7 nights Caribbean Getaway,GO TO: www.investsourceinc.com.
To hear "The Fastest 60 Seconds in the Small-Cap Market," please goto www.ceo-corner.com This opinion contains forward-lookingstatements that involve risks and uncertainties. This material isfor informational purposes only and should not be construed as anoffer or solicitation to buy or sell securities. InvestSource, Inc.has prepared all material herein based upon information believed tobe reliable. The information contained herein is not guaranteed byInvestSource, Inc. to be accurate, and should not be considered tobe all-inclusive. The companies that are discussed in this releasehave not given an opinion or approved the statements made in thisrelease.
InvestSource, Inc. is not a licensed broker, broker dealer, marketmaker, investment banker, investment advisor, analyst orunderwriter. InvestSource, Inc. affiliates, officers, directors andemployees may also have bought, or may buy the shares discussed inthis opinion and may profit in the event of a rise in value.InvestSource, Inc. will not advise as to when it decides to selland does not, and will not, offer any opinion as to when othersshould buy or sell; each investor must make that decision based onhis or her judgment of the market. Please consult your brokerbefore purchasing or selling any securities mentioned herein.InvestSource has agreed to be compensated 75,000 unrestrictedshares of HYII for services rendered. To view full disclaimers,please go to http://investsourceinc.com/php/disclaimer.php(disclaimers).
CONTACT: InvestSource, Inc WWW: http://www.investsourceinc.com
(M2 Communications Ltd disclaims all liability for informationprovided within M2 PressWIRE. Data supplied by named party/parties.Further information on M2 PressWIRE can be obtained athttp://www.presswire.net on the world wide web. Inquiries toinfo@m2.com).
Copyright 2008 M2 Communications Ltd.
Provider:
M2 Communications / M2 PressWIRE
Keywords:
Business Management , U.S. Business News , Business News , Obituaries & Deaths , Entertainment Business News , Executive Personnel Changes , Executive Turnover , Health & Family , Top World News , Americas , North America , Equestrian Events & Horse Racing , Healthcare , Hot News - Devices , HR & Labor Management , North American HR Labor Management , Drug Regulatory Process - Non U.S. , USA , Major Corporations , Medical Device Business News , Major Medical Device Firms , Medical Device Regulatory , Medical Devices , Healthcare Busines